why choose us

First received: August 09, 2022

Clinical Trial: A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Study Status: Completed

Recruit Status: RECRUITING

Condition: Endometrioid Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

Brief Summary: The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian cancer, high-grade serous ovarian cancer, or cervical cancer.

Read more